SAINT neuromodulation enters a small feasibility test in older adults with depression and memory complaints
A new open-label feasibility trial is taking Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT®, into a population where depression and cognitive symptoms often overlap and where treatment decisions can become especially difficult. The study is enrolling adults 65 years and older with treatment-resistant depression and memory concerns, then asking a practical question: can an accelerated, MRI-guided transcranial magnetic stimulation protocol be delivered safely while also producing measurable changes in memory, mood, and day-to-day function?
The trial is intentionally small, with an estimated enrollment of 20 participants, and it has no placebo group. Every enrolled participant receives the same intervention, which makes this a feasibility study rather than a comparative efficacy trial. In clinical terms, that means the first task is not to prove superiority over sham or standard care. The first task is to determine whether this intensive neuromodulation schedule can be carried out in older adults who already carry a heavy symptom burden and who may also have underlying biomarker evidence of neurodegenerative change.
Depression in later life can blur into complaints of slowed thinking, poor recall, reduced concentration, and reduced independence. A therapy that could alter mood and cognition together would be clinically attractive, but the overlap also creates interpretive risk. Improvement in depressive symptoms may lift attention and memory performance without changing the underlying cognitive disorder, while a fixed cognitive deficit may remain even if mood improves. This study is built around that uncertainty.
MRI-guided stimulation is aimed at a left prefrontal target tied to mood circuitry
SAINT® uses magnetic resonance imaging to personalize the stimulation target within the left prefrontal cortex, a region linked to mood regulation and connected brain networks. The treatment is delivered through the Magnus Neuromodulation System, which combines a TMS stimulator, coil, neuronavigation, and software that uses structural and functional MRI information to identify the individualized target. The biological rationale is straightforward: if dysregulated prefrontal circuits help sustain depressive symptoms, repeated stimulation may shift network activity toward a healthier state and improve affective symptoms, with downstream effects on cognition and function.
The protocol is intensive. Participants receive 10 stimulation sessions per day for 5 consecutive days, for a total of 50 sessions. Each session lasts about 10 minutes, with roughly 50 minutes between sessions. That accelerated intermittent theta-burst schedule is designed to compress treatment into a brief window, which may be convenient for patients and families, but it also raises the bar for tolerability, monitoring, and adherence. Older adults with depression frequently have additional medical complexity, and the study’s structure reflects that reality.
The primary efficacy assessment centers on change in global cognitive function from baseline to about 5 days after the treatment course ends. Secondary and exploratory measures extend beyond cognition to depressive symptoms, clinician-rated global improvement and severity, self-reported cognitive concerns, and the ability to carry out daily activities. Follow-up continues for as long as 12 months, giving investigators a chance to see whether any gains persist after the immediate stimulation period has passed.
Safety monitoring is built around seizure risk, mood destabilization, and daily neurologic checks
Because transcranial magnetic stimulation is noninvasive but still brain-directed, safety surveillance is extensive. Participants undergo memory, mood, and health assessments and an MRI scan before treatment. During the active course, trained staff observe them during stimulation sessions and perform daily checks for neurological symptoms, mood elevation, worsening depression, suicidal thoughts or behaviors, and other adverse effects. Hearing protection is used during all stimulation sessions.
The protocol also includes predefined stopping rules for individual participants and for the study itself if important safety concerns appear. Those protections are especially relevant in older adults, who may have comorbid neurologic disease, vascular brain injury, or medication exposures that can alter seizure threshold or complicate adverse-event interpretation. Exclusion criteria remove people with epilepsy, seizure disorders, implanted devices incompatible with TMS or MRI, clinically significant MRI abnormalities, unstable medical illness, and psychiatric diagnoses beyond major depressive disorder that could interfere with safe participation.
There is also a deliberate attempt to avoid enrolling people whose brain health profile may distort interpretation of the results. Eligibility requires a recent amyloid PET scan and/or a Lumipulse G pTau217/Amyloid 1-42 blood test performed as part of usual care within 6 months before baseline. Investigators plan to explore whether treatment effects differ by amyloid or tau-related biomarker status. In practical terms, that means the study is not treating all late-life depression as biologically identical. Some participants may have depressive illness with memory complaints layered on top of a neurodegenerative process, while others may not.
A narrow feasibility study may still influence how future cognitive depression trials are built
The study’s design makes its limits as important as its aims. There is no comparator arm, no blinding, and only a small sample. Those features prevent causal claims about efficacy. Any changes in memory or mood could reflect regression to the mean, expectancy effects, intensified clinical attention, or the natural fluctuation of depressive symptoms. Even so, a feasibility study can answer an essential question for this field: whether a highly accelerated, individualized TMS approach is workable in older adults with both depressive and cognitive complaints.
Age eligibility begins at 65 years, and the trial accepts all sexes while excluding healthy volunteers. Participants must have treatment-resistant depression, current depressive symptoms with a Montgomery-Asberg Depression Rating Scale score of at least 20, a reported memory concern, and a Mini-Mental State Examination score between 10 and 28. Insurance coverage for rTMS/SAINT treatment is also required, along with willingness to follow medication restrictions and study visits.
The final clinical question is not whether a single protocol can solve the problem of late-life depression with memory complaints. It cannot. The more focused question is whether MRI-guided accelerated TMS can be administered safely, whether early cognitive and mood signals appear after the 5-day course, and whether those signals persist across months of follow-up. Enrollment is expected to begin in October 2026, with primary completion projected for January 2029 and study completion in February 2029. Until then, the field will have only the design, not the results, and the absence of a control group will remain the central constraint on any interpretation of benefit.